Physician

Robert T Muldoon, M.D.

According to 2025 Medicare claims, Robert Muldoon, M.D. (NPI: 1841277589) practices hematology/oncology in the Hot Springs, AR market, with the plurality of this provider's patient population coming from Garland, AR. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 71913-5417. Muldoon is affiliated with the Baptist Health/UAMS Accountable Care Alliance (ACO ID: A3633), participating under the MSSP model.

Muldoon's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,257 traditional Medicare patients, billed 368,912 HCPCS/CPT codes, and received $6,893,249 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,241 prescription claims across 327 beneficiaries totaling $3,944,429 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 92 claims. Open Payments data shows 143 records totaling $182,891. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,020,821 to $6,893,249. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $2,792,706 and ending at $3,944,429. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $18,587 to $3,895.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	734	229,648	$2,020,821
2016	721	305,670	$3,171,657
2017	659	302,144	$3,516,927
2018	734	306,453	$3,989,903
2019	990	414,785	$5,136,783
2020	942	416,015	$6,393,516
2021	876	276,425	$4,164,935
2022	1,024	348,574	$4,484,919
2023	1,148	342,682	$5,285,828
2024	1,257	368,912	$6,893,249

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	290	2,161	$2,792,706
2016	273	2,287	$3,757,135
2017	297	2,393	$4,893,246
2018	304	2,209	$4,629,656
2019	288	1,939	$3,949,751
2020	264	1,755	$3,193,068
2021	299	1,987	$3,357,621
2022	308	1,936	$3,637,851
2023	305	1,894	$2,945,652
2024	327	2,241	$3,944,429

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	25	291	$77,529
2016	28	307	$72,291
2017	49	283	$46,647
2018	34	255	$32,708
2019	11	111	$14,665
2020	11	126	$11,016
2021	33	214	$14,883
2022	29	167	$7,529
2023	N/R	99	$15,020
2024	N/R	92	$4,346

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	331	887	$87
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	498	1,160	$59
96372	Injection of drug or substance under skin or into muscle	264	1,091	$10
36415	Insertion of needle into vein for collection of blood sample	911	2,630	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	855	2,431	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	49	1,470	$680,996
Xtandi	Enzalutamide	34	1,020	$451,011
Ojjaara	Momelotinib Dihydrochloride	13	390	$357,017
Brukinsa	Zanubrutinib	23	690	$335,803
Zejula	Niraparib Tosylate	11	330	$202,609

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	38	$2,748
J8521	Capecitabine, oral, 500 mg	N	N/R	26	$1,109
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	28	$489

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	141	$2,616	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$180,275	Aveo Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert T. Muldoon, M.D.?

Tedicare shows public-source Medicare data for Robert T. Muldoon, M.D. (NPI 1841277589), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert T. Muldoon, M.D. have ACO affiliation data?

Robert T. Muldoon, M.D. is shown with ACO affiliation data for Baptist Health/UAMS Accountable Care Alliance (MSSP, ACO ID A3633).

What billing organization is linked to Robert T. Muldoon, M.D.?

Robert T. Muldoon, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Robert T. Muldoon, M.D. have Open Payments data?

Robert T. Muldoon, M.D. has 143 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.